1 / 1

HOME

HOME. Micro- and macrovascular complications: 31% with metformin vs. 28% with placebo Macrovascular complications: 15% vs. 18%, respectively Microvascular complications: 17% vs. 15% (adjusted p value = 0.43), respectively.

armani
Télécharger la présentation

HOME

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HOME Micro- and macrovascular complications: 31% with metformin vs. 28% with placebo Macrovascular complications: 15% vs. 18%, respectively Microvascular complications: 17% vs. 15% (adjusted p value = 0.43), respectively Trial design: Patients with type 2 diabetes were randomized to 850 mg of metformin (n = 196) versus placebo (n = 194) 1-3 times daily. Mean follow-up was 4.3 years. Results (Adjusted p value = 0.33) (Adjusted p value = 0.04) 31 28 % 18 15 Conclusions • Among patients with type 2 diabetes, the addition of metformin to insulin does not reduce combined micro- and macrovascular complications over 4.3 years of follow-up • Metformin may reduce macrovascular complications Micro- and macrovascular complications Macrovascular complications Metformin plus insulin Placebo plus insulin Kooy A, et al. Arch Intern Med 2009;169:616-25

More Related